Phase 3 Hemophilia B Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Hemophilia AHemophilia B
Pfizer173 enrolled17 locationsNCT05568719
Recruiting
Phase 3
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Hemophilia B
CSL Behring20 enrolled10 locationsNCT07080905
Recruiting
Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Hemophilia AHemophilia B
Pfizer100 enrolled66 locationsNCT05611801
Recruiting
Phase 3
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Hemophilia B
CSL Behring35 enrolled26 locationsNCT06003387
Recruiting
Phase 3
An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Hemophilia B
Biocad24 enrolled14 locationsNCT06700096